288 assets in Lymphoma

Therapeutic assets addressing Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
cd22 car-t Lymphoma	Seattle Children's Hospital	P1	C (37)
cs08399 Lymphoma	Chipscreen Biosciences, Ltd.	P1	C (37)
Ebv-Specific T Cells: B Lymphoma	Baylor College of Medicine	P1	C (37)
Edotreotide Lymphoma	ITM Solucin GmbH	P1	C (37)
Fluoroglutamine (2S,4R) Lymphoma	Memorial Sloan Kettering Cancer Center	P1	C (37)
Former Process Shr2554 、New Process Shr2554 Lymphoma	Jiangsu HengRui Medicine Co., Ltd.	P1	C (37)
Gamitrinib Lymphoma	Fox Chase Cancer Center	P1	C (37)
Grc 54276 Lymphoma	Glenmark Specialty S.A.	P1	C (37)
hg146 Lymphoma	HitGen Inc.	P1	C (37)
ic9-car19 t cells Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	C (37)
Icovamenib Lymphoma	Biomea Fusion Inc.	P1	C (37)
JS014 Lymphoma	Anwita Biosciences	P1	C (37)
Kappa Cd28 T Cells Lymphoma	Baylor College of Medicine	P1	C (37)
lb1410 Lymphoma	L & L Bio Co., Ltd., Ningbo, China	P1	C (37)
Scri-Hucar19V2 Lymphoma	Seattle Children's Hospital	P1	C (37)
sg2501 Lymphoma	Hangzhou Sumgen Biotech Co., Ltd.	P1	C (37)
t-1301 capsules Lymphoma	Taivex Therapeutics Corporation	P1	C (37)
Tgfbeta Resistant Lmp-Specific Ctls Lymphoma	Baylor College of Medicine	P1	C (37)
Tln-121 Lymphoma	Treeline Biosciences, Inc.	P1	C (37)
Tln-254 Lymphoma	Treeline Biosciences, Inc.	P1	C (37)
tp53-epha-2-car-dc Lymphoma	Chinese PLA General Hospital	P1	C (37)
vp301 Lymphoma	Virtuoso BINco, Inc.	P1	C (37)
1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer Lymphoma	Pfizer	P1	C (36)
Bisoprolol Fumarate Lymphoma	University of Arizona	Early P1	C (34)
Brexucabtagene Autoleucel Lymphoma	M.D. Anderson Cancer Center	Early P1	C (34)
Hyaluronidase Fihj Lymphoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Early P1	C (34)
Isoproterenol Lymphoma	University of Arizona	Early P1	C (34)
Nadolol Lymphoma	University of Arizona	Early P1	C (34)
Rivogenlecleucel Lymphoma	Bellicum Pharmaceuticals	P1/2	C (34)
Roflumilast Lymphoma	University of Arizona	Early P1	C (34)
Simvastatin Lymphoma	Masonic Cancer Center, University of Minnesota	Early P1	C (34)
ds-3201b Lymphoma	Daiichi Sankyo Co., Ltd.	P1	D (30)
Human Faecal Matter Lymphoma	University Health Network, Toronto	N/A	D (30)
kl-7shrna Lymphoma	Affiliated Hospital of Guangdong Medical University	N/A	D (28)
Rivaroxaban Lymphoma	Medical University of Gdansk	N/A	D (28)
emb07 Lymphoma	EpimAb Biotherapeutics (Suzhou)Co., Ltd.	P1	NR ()
Rec-1245 Lymphoma	Recursion Pharmaceuticals Inc.	P1/2	NR ()
Rgl-305 Lymphoma	Fudan University	N/A	NR ()

Showing 251 to 288 of 288 assets

PreviousPage 6 of 6Next